Lima Cid A, Jammal Millena P, Martins-Filho Agrimaldo, Silveira Thales Parenti, Micheli Douglas C, Tavares-Murta Beatriz M, Murta Eddie F C, Nomelini Rosekeila Simões
Research Institute of Oncology (IPON)/Discipline of Gynecology and Obstetrics, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Gynecol Obstet Invest. 2018;83(1):35-39. doi: 10.1159/000473891. Epub 2017 May 12.
BACKGROUND/AIMS: Growth differentiation factor 15 (GDF-15) is induced by pro-inflammatory cytokines. Higher levels of GDF-15 have been associated with malignancy. The aim of the study was to evaluate both tissue and serum levels of GDF-15 in ovarian neoplasms.
A cohort study evaluated 31 patients with benign ovarian tumors and 34 patients with ovarian cancer were evaluated in 2 years. The inclusion criterion was histopathological diagnosis of ovarian epithelial neoplasia. Exclusion criteria were secondary malignant ovarian neoplasia and preoperative treatment. Serum and tissue levels of GDF-15 were assessed by enzyme-linked immunosorbent assay and immunohistochemistry, respectively. Chi-square test and unpaired t test were performed.
Serum levels were higher in the patients with malignant neoplasms than in the patients with benign tumors, yet the difference was not statistically significant. GDF-15 immunostaining was significantly more frequent in the stroma of the malignant tumors than in the stroma of the benign tumors (p = 0.0034).
GDF-15 staining is elevated in the stroma of ovarian cancer, demonstrating that it may be a potential diagnostic and therapeutic target.
背景/目的：生长分化因子15（GDF - 15）由促炎细胞因子诱导产生。较高水平的GDF - 15与恶性肿瘤有关。本研究旨在评估卵巢肿瘤组织和血清中GDF - 15的水平。
一项队列研究在两年内评估了31例卵巢良性肿瘤患者和34例卵巢癌患者。纳入标准为卵巢上皮性肿瘤的组织病理学诊断。排除标准为继发性恶性卵巢肿瘤和术前治疗。分别采用酶联免疫吸附测定法和免疫组织化学法评估血清和组织中GDF - 15的水平。进行卡方检验和非配对t检验。
恶性肿瘤患者的血清水平高于良性肿瘤患者，但差异无统计学意义。GDF - 15免疫染色在恶性肿瘤间质中的出现频率显著高于良性肿瘤间质（p = 0.0034）。
GDF - 15染色在卵巢癌间质中升高，表明它可能是一个潜在的诊断和治疗靶点。
